Dimensional Fund Advisors LP Purchases 35,957 Shares of OptimizeRx Co. (NASDAQ:OPRX)

Dimensional Fund Advisors LP grew its position in OptimizeRx Co. (NASDAQ:OPRX) by 12.5% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 324,130 shares of the company’s stock after acquiring an additional 35,957 shares during the period. Dimensional Fund Advisors LP owned about 1.77% of OptimizeRx worth $3,241,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of OPRX. Rice Hall James & Associates LLC grew its holdings in OptimizeRx by 23.5% during the second quarter. Rice Hall James & Associates LLC now owns 496,135 shares of the company’s stock worth $4,961,000 after purchasing an additional 94,253 shares during the period. Rhumbline Advisers lifted its position in shares of OptimizeRx by 9.2% in the second quarter. Rhumbline Advisers now owns 31,462 shares of the company’s stock valued at $315,000 after buying an additional 2,658 shares during the last quarter. Legato Capital Management LLC boosted its stake in shares of OptimizeRx by 74.0% during the 2nd quarter. Legato Capital Management LLC now owns 59,693 shares of the company’s stock worth $597,000 after acquiring an additional 25,377 shares during the period. Summit Securities Group LLC acquired a new position in shares of OptimizeRx during the 2nd quarter worth approximately $25,000. Finally, Bank of New York Mellon Corp increased its holdings in shares of OptimizeRx by 9.9% during the 2nd quarter. Bank of New York Mellon Corp now owns 111,719 shares of the company’s stock worth $1,117,000 after acquiring an additional 10,041 shares during the last quarter. 76.47% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

OPRX has been the subject of a number of research analyst reports. B. Riley assumed coverage on shares of OptimizeRx in a research report on Thursday, July 25th. They set a “buy” rating and a $18.50 price objective for the company. Royal Bank of Canada decreased their price target on shares of OptimizeRx from $17.00 to $14.00 and set an “outperform” rating on the stock in a research note on Friday, August 16th. JMP Securities reissued a “market outperform” rating and issued a $16.00 price target on shares of OptimizeRx in a report on Friday, June 21st. Finally, Barclays reduced their price objective on OptimizeRx from $15.00 to $11.00 and set an “equal weight” rating for the company in a report on Monday, August 12th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $14.50.

OptimizeRx Trading Up 2.8 %

OPRX stock opened at $6.57 on Friday. OptimizeRx Co. has a 52 week low of $6.30 and a 52 week high of $16.65. The company has a debt-to-equity ratio of 0.27, a quick ratio of 3.07 and a current ratio of 3.07. The company’s 50-day simple moving average is $7.95 and its 200 day simple moving average is $9.87. The company has a market capitalization of $120.03 million, a PE ratio of -6.44 and a beta of 1.27.

OptimizeRx (NASDAQ:OPRX) last announced its earnings results on Thursday, August 8th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.11. OptimizeRx had a negative net margin of 21.53% and a negative return on equity of 5.97%. The firm had revenue of $18.81 million for the quarter, compared to analyst estimates of $20.47 million. As a group, sell-side analysts anticipate that OptimizeRx Co. will post -0.33 earnings per share for the current year.

OptimizeRx Company Profile

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.